General Information of Drug (ID: DM8N3OQ)

Drug Name
GT-AADC Drug Info
Indication
Disease Entry ICD 11 Status REF
Aromatic L-amino acid decarboxylase deficiency 5C59.00 Phase 2 [1]
Cross-matching ID
TTD Drug ID
DM8N3OQ

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Vitamin B6 DMDBZMV Vitamin B6 deficiency 5B5D Approved [2]
Carbidopa DMHRG8Q Parkinson disease 8A00.0 Approved [3]
Patrome DM3H2U4 Parkinson disease 8A00.0 Phase 3 [4]
Benserazide DMLU8NX N. A. N. A. Phase 3 [3]
AV-201 DMDL9WU Parkinson disease 8A00.0 Phase 2 [5]
VY-AADC DMPSBTL Parkinson disease 8A00.0 Phase 2 [6]
PTC-AADC DM9ZHE3 Aromatic L-amino acid decarboxylase deficiency 5C59.00 Phase 2 [7]
ProSavin DMJ42E6 Parkinson disease 8A00.0 Phase 1/2 [8]
OXB-102 DMXF9DM Parkinson disease 8A00.0 Phase 1/2 [9]
VY-AADC01 DM0N71R Parkinson disease 8A00.0 Phase 1 [10]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Aromatic-L-amino-acid decarboxylase (DDC) TTN451K DDC_HUMAN Replacement [1]

References

1 Clinical pipeline report, company report or official report of PTC Therapeutics.
2 Functional COMT variant predicts response to high dose pyridoxine in Parkinson's disease. Am J Med Genet B Neuropsychiatr Genet. 2005 Aug 5;137B(1):1-4.
3 Catechol-O-methyltransferase inhibitors in the management of Parkinson's disease. Semin Neurol. 2001;21(1):15-22.
4 The aromatic-L-amino acid decarboxylase inhibitor carbidopa is selectively cytotoxic to human pulmonary carcinoid and small cell lung carcinoma cells. Clin Cancer Res. 2000 Nov;6(11):4365-72.
5 UCSF report
6 Clinical pipeline report, company report or official report of Voyager Therapeutics.
7 ClinicalTrials.gov (NCT04903288) An Open-Label Trial to Address the Safety of the SmartFlow MR-Compatible Ventricular Cannula for Administering Eladocagene Exuparvovec to Pediatric Subjects. U.S.National Institutes of Health.
8 Clinical pipeline report, company report or official report of Oxford BioMedica.
9 Clinical pipeline report, company report or official report of Oxford BioMedica.
10 Safety of AADC Gene Therapy for Moderately Advanced Parkinson Disease: Three-Year Outcomes From the PD-1101 Trial. Neurology. 2022 Jan 4;98(1):e40-e50.